Endo International PLC (ENDP) & Biodel (ALBO) Head to Head Survey

Biodel (NASDAQ: ALBO) and Endo International PLC (NASDAQ:ENDP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitabiliy, dividends, analyst recommendations, institutional ownership, earnings and risk.

Insider & Institutional Ownership

12.4% of Biodel shares are held by institutional investors. Comparatively, 92.8% of Endo International PLC shares are held by institutional investors. 22.3% of Biodel shares are held by company insiders. Comparatively, 0.5% of Endo International PLC shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Biodel and Endo International PLC’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	EBITDA	Earnings Per Share	Price/Earnings Ratio
Biodel	$11.24 million	14.27	-$10.33 million	N/A	N/A
Endo International PLC	$4.08 billion	0.57	$411.84 million	($15.20)	-0.69

Endo International PLC has higher revenue and earnings than Biodel.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Biodel and Endo International PLC, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodel	0	0	4	0	3.00
Endo International PLC	0	14	5	0	2.26

Biodel currently has a consensus target price of $35.00, indicating a potential upside of 37.25%. Endo International PLC has a consensus target price of $16.94, indicating a potential upside of 61.19%. Given Endo International PLC’s higher probable upside, analysts clearly believe Endo International PLC is more favorable than Biodel.

Risk and Volatility

Biodel has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Endo International PLC has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.

Profitability

This table compares Biodel and Endo International PLC’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biodel	N/A	N/A	N/A
Endo International PLC	-82.93%	25.32%	6.90%

Summary

Endo International PLC beats Biodel on 7 of the 12 factors compared between the two stocks.

Biodel Company Profile

Biodel Inc. is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia. It also develops insulin formulations for Type 1 and Type 2 diabetes patients. Its product pipeline includes RHI-based Ultra-Rapid-Acting Insulin, Analog-based Ultra-Rapid-Acting Insulin, Concentrated Ultra-Rapid-Acting Insulin and Glucagon. The Company’s BIOD-531 is a Concentrated Ultra-Rapid-Acting Insulin and its insulin analog-based ultra-rapid-acting insulin product candidates include BIOD-123, BIOD-531, BIOD-238 and BIOD-250. It also conducts pre-clinical testing to develop liquid formulations of glucagon for hypoglycemic rescue and other indications.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc. is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel. The Company operates in three segments: Endo Pharmaceuticals, Qualitest and AMS. In June 2014, the Company’s subsidiary, Endo Pharmaceuticals sold its pharmaceutical drug discovery platform to AsanaBioSciences, LLC. In June 2014, Asana BioSciences, LLC, an independent member of Amneal Alliance of Companies, acquired early-stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International plc. In June 2014, Trendlines Group acquired intellectual property developed within the framework of an R&D agreement with the Company. In July 2014, it acquired Grupo Farmaceutico Somar.